1.1. Maria A. Introduction to modeling and simulation. Winter Simulation Conference; 1997.
1.2. 日本製薬工業協会 医薬品評価委員会 統計・DM 部会(平成 24 年 3 月)『新医薬品開発戦略 新たなナレッジマネジメントの潮流(Model-Based Drug Development 解説)』医薬出版センター
1.3. Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today. 2008;13(7-8):341-6.
1.4. Burman CF HB, Olsson P. Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics. 2005;4:47-58.
1.5. アステラス製薬株式会社 セロクエル®25mg 錠 添付文書
1.6. Medic G, Higashi K, Littlewood KJ, Diez T, Granstrom O, Kahn RS. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2013;9:119-31.
1.7. Cristancho MA, Thase ME. The role of quetiapine extended release in the treatment of bipolar depression. Adv Ther. 2010;27(11):774-84.
1.8. Eriksson L, Hallerback T, Jorgensen L, Carlborg A. Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study. Ther Adv Psychopharmacol. 2012;2(6):217-26.
1.9. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
1.10. Chavda HV PC, Anand IS. Biopharmaceutics classification system. Systematic Reviews in Pharmacy. 2010;1(1):62-9.
1.11. アステラス製薬株式会社. ビプレッソ徐放錠 申請概要.
1.12. Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):199-204.
1.13. 川上憲人. うつ病の疫学と国際比較. 日本臨床. 2007;65(9):1578-84.
1.14. Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet. 2002;359(9302):241-7.
1.15. 寺尾岳・和田明彦(2010)『双極性障害の診断・治療と気分安定薬の作用機序』東京:新興医学出版社
1.16. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61 Suppl 9:47-51.
1.17. Isometsa E. Course, outcome and suicide risk in bipolar disorder: a review. Psychiatria Fennica. 1993(24):113-24.
1.18. 抗うつ薬の臨床評価方法に関するガイドライン. 薬食審査発 1116 第 1 号(平成 22 年 11 月 16 日)
1.19. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl). 1993;112(2-3):285-92.
1.20. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl). 1998;135(2):119-26.
1.21. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment- resistant depression and anxiety. J Clin Psychiatry. 2005;66 Suppl 8:30-40.
1.22. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clinical Pharmacokinetics. 2001;40(7):509-22.
1.23. Nyberg S, Jucaite A, Takano A, Kagedal M, Cselenyi Z, Halldin C, et al. Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR. Int J Neuropsychopharmacol. 2013;16(10):2235-44.
1.24. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007;8(9):1211-9.
1.25. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8.
1.26. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002;956(2):349-57.
1.27. Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol. 2004;504(1-2):61-4.
1.28. 杉岡信幸、高田寛治. 薬物動態解析. Medical Technology. 2008;36(3):252-6.
1.29. Murasaki M, Koyama T, Kanba S, Takeuchi M, Shimizu Y, Arita E, et al. Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology (Berl). 2018;235(10):3079-80.
1.30. Kanba S, Murasaki M, Koyama T, Takeuchi M, Shimizu Y, Arita E, et al. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non- controlled extension study in Japanese patients with bipolar depression. BMC Psychiatry. 2019;19(1):198.
1.31. Food and Drug Administration. Guidance for Industry. Population Pharmacokinetics. February 1999.
1.32. European Medicines Agency. Draft guideline on reporting the results of pharmacokinetic analyses. 2006.
1.33. 母集団薬物動態/薬力学解析ガイドライン. 薬生薬審発 515 第 1 号(令和元年 5 月 15 日)
1.34. Wang Y. Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn. 2007;34(5):575-93.
1.35. Kimko HC, Reele SS, Holford NH, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther. 2000;68(5):568-77.
1.36. Zhou D, Bui KH, Li J, Al-Huniti N. Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. J Clin Pharmacol. 2015;55(11):1248-55.
1.37. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-51.
1.38. Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-60.
1.39. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-9.
1.40. 船渡川伊久子・船渡川隆. 母集団薬物動態解析の基礎:線形混合効果モデル・非線形混合効果モデルの数理. 計量生物学. 2016;36:S33-S48.
1.41. The Clinical Evaluation of QT/QTc Interval Prolongation andProarrhythmic Potential for Non- Antiarrhythmic Drugs: E14.Geneva, Switzerland: International Conference on Harmonizationof Technical Requirements for Registration of Pharmaceuticals for Human Use.
1.42. Di Iorio B, Bellasi A. QT interval in CKD and haemodialysis patients. Clin Kidney J. 2013;6(2):137- 43.
1.43. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6(11):904-16.
1.44. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y. Haloperidol-induced torsades de pointes. Chest. 1990;98(2):482-4.
1.45. Bonate PL. The effects of active metabolites on parameter estimation in linear mixed effect models of concentration-QT analyses. J Pharmacokinet Pharmacodyn. 2013;40(1):101-15.
1.46. Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45(3):383-97.
1.47. Chapel S, Hutmacher MM, Haig G, Bockbrader H, de Greef R, Preskorn SH, et al. Exposure- response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol. 2009;49(11):1297-308.
1.48. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33(1):3-10.
1.49. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol. 2003;8(4):343-51.
1.50. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Final Concept Paper. Pediatric Extrapolation. (ICH-E11A) 2017 Oct.
1.51. European Medicines Agency. Reflection paper on the use of extrapolation in the development of medicines for paediatrics. 2018 Oct.
1.52. Food and Drug Administration. Draft Guidance for Industry: General clinical pharmacology considerations for pediatric studies for drugs and biological products. 2014 Dec.
1.53. EFPIA MID3 Workgroup; Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, et al. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93-122.
1.54. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 臨床試験の一般指針(ICH-E8). 1998 Apr 21.
1.55. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-96.
1.56. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
1.57. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl. 1978(271):5-27.